A. D. Beadell Investment Counsel Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

A. D. Beadell Investment Counsel Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 56.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,836 shares of the biopharmaceutical company’s stock after buying an additional 15,900 shares during the quarter. A. D. Beadell Investment Counsel Inc.’s holdings in Pfizer were worth $1,268,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer during the second quarter valued at about $29,000. Quarry LP purchased a new stake in Pfizer in the second quarter worth about $31,000. Creekmur Asset Management LLC purchased a new stake in Pfizer in the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 2.2 %

Shares of NYSE:PFE traded down $0.65 during trading on Thursday, hitting $29.54. 14,971,007 shares of the company were exchanged, compared to its average volume of 37,327,754. The stock has a market capitalization of $167.39 billion, a P/E ratio of -496.00, a PEG ratio of 1.23 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $33.92. The firm’s 50 day moving average price is $29.09 and its 200-day moving average price is $28.36.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 EPS. On average, research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.69%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PFE shares. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.